Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)

Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground b...

Full description

Saved in:
Bibliographic Details
Published inMolecular autism Vol. 9; no. 1; pp. 12 - 13
Main Authors Stivaros, Stavros, Garg, Shruti, Tziraki, Maria, Cai, Ying, Thomas, Owen, Mellor, Joseph, Morris, Andrew A., Jim, Carly, Szumanska-Ryt, Karolina, Parkes, Laura M, Haroon, Hamied A., Montaldi, Daniela, Webb, Nicholas, Keane, John, Castellanos, Francisco X., Silva, Alcino J., Huson, Sue, Williams, Stephen, Gareth Evans, D., Emsley, Richard, Green, Jonathan
Format Journal Article
LanguageEnglish
Published London BioMed Central 22.02.2018
BioMed Central Ltd
BMC
Subjects
Autism
Autistic Disorder - blood
Autistic Disorder - complications
Autistic Disorder - drug therapy
Biomarkers - blood
Brain - diagnostic imaging
Child
Complications and side effects
Dosage and administration
Drug therapy
Emerging rare genetic and genomic syndromes in autism and developmental delay
Female
gamma-Aminobutyric Acid - blood
Glutamic Acid - blood
Human Genetics
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
Medicine
Medicine & Public Health
Mitogen-Activated Protein Kinases - blood
Neurofibromatosis
Neurofibromatosis 1 - blood
Neurofibromatosis 1 - complications
Neurofibromatosis 1 - drug therapy
Neurofibromatosis type 1
Neuroimaging
Neurology
Neuropsychology
Neurosciences
Patient outcomes
Pediatrics
Psychiatry
Psychological aspects
Randomised controlled trial
Simvastatin
Simvastatin - administration & dosage
Simvastatin - adverse effects
Simvastatin - therapeutic use
Statin
United Kingdom
Neuroimaging
Autism
Neurofibromatosis type 1
Statin
Simvastatin
Randomised controlled trial
Online AccessGet full text
ISSN2040-2392
2040-2392
DOI10.1186/s13229-018-0190-z

Cover

Abstract Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. Methods A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Results Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA ( t (12) = − 2.12, p  = .055), GABA/Glx ratio ( t (12) = − 2.78, p  = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p  < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p  < 0.01). Machine-learning classification of imaging outcomes achieved 79% ( p  < .05) accuracy differentiating groups at endpoint against chance level (64%, p  = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for behavioural outcome. Conclusions We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. Trial registration EU Clinical Trial Register (EudraCT) 2012-005742-38 ( www.clinicaltrialsregister.eu )
AbstractList Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. Methods A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Results Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA ( t (12) = − 2.12, p  = .055), GABA/Glx ratio ( t (12) = − 2.78, p  = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p  < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p  < 0.01). Machine-learning classification of imaging outcomes achieved 79% ( p  < .05) accuracy differentiating groups at endpoint against chance level (64%, p  = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for behavioural outcome. Conclusions We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. Trial registration EU Clinical Trial Register (EudraCT) 2012-005742-38 ( www.clinicaltrialsregister.eu )
Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. Methods A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Results Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = - 2.12, p = .055), GABA/Glx ratio (t(12) = - 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome. Conclusions We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. Trial registration EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu) Keywords: Autism, Neurofibromatosis type 1, Neuroimaging, Randomised controlled trial, Statin, Simvastatin
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = - 2.12, p = .055), GABA/Glx ratio (t(12) = - 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome. We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network.
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA ( (12) = - 2.12,  = .055), GABA/Glx ratio ( (12) = - 2.78,  = .016), and reduced grey nuclei Glx (ANCOVA < 0.05, Mann-Whitney < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney  < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney  < 0.01). Machine-learning classification of imaging outcomes achieved 79% (  < .05) accuracy differentiating groups at endpoint against chance level (64%,  = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome. We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu).
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes.BackgroundNeurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes.A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression).MethodsA single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression).Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = - 2.12, p = .055), GABA/Glx ratio (t(12) = - 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome.ResultsThirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = - 2.12, p = .055), GABA/Glx ratio (t(12) = - 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome.We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network.ConclusionsWe show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network.EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu).Trial registrationEU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu).
Abstract Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. Methods A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Results Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = − 2.12, p = .055), GABA/Glx ratio (t(12) = − 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for behavioural outcome. Conclusions We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. Trial registration EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu)
ArticleNumber 12
Audience Academic
Author Webb, Nicholas
Cai, Ying
Thomas, Owen
Garg, Shruti
Mellor, Joseph
Keane, John
Emsley, Richard
Jim, Carly
Parkes, Laura M
Gareth Evans, D.
Huson, Sue
Stivaros, Stavros
Green, Jonathan
Morris, Andrew A.
Montaldi, Daniela
Szumanska-Ryt, Karolina
Castellanos, Francisco X.
Williams, Stephen
Tziraki, Maria
Haroon, Hamied A.
Silva, Alcino J.
Author_xml – sequence: 1
  givenname: Stavros
  surname: Stivaros
  fullname: Stivaros, Stavros
  organization: Academic Unit of Paediatric Radiology, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 2
  givenname: Shruti
  surname: Garg
  fullname: Garg, Shruti
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust
– sequence: 3
  givenname: Maria
  surname: Tziraki
  fullname: Tziraki, Maria
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 4
  givenname: Ying
  surname: Cai
  fullname: Cai, Ying
  organization: Departments of Neurobiology, Psychiatry and Biobehavioral Sciences and Psychology, Integrative Center for Learning and Memory, Brain Research Institute, Brain Research Institute, University of California
– sequence: 5
  givenname: Owen
  surname: Thomas
  fullname: Thomas, Owen
  organization: Academic Unit of Radiology, Salford Royal Foundation NHS Trust, Manchester Academic Health Sciences Centre
– sequence: 6
  givenname: Joseph
  surname: Mellor
  fullname: Mellor, Joseph
  organization: Computer Science, University of Manchester
– sequence: 7
  givenname: Andrew A.
  surname: Morris
  fullname: Morris, Andrew A.
  organization: Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre
– sequence: 8
  givenname: Carly
  surname: Jim
  fullname: Jim, Carly
  organization: Manchester Metropolitan University
– sequence: 9
  givenname: Karolina
  surname: Szumanska-Ryt
  fullname: Szumanska-Ryt, Karolina
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 10
  givenname: Laura M
  surname: Parkes
  fullname: Parkes, Laura M
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 11
  givenname: Hamied A.
  surname: Haroon
  fullname: Haroon, Hamied A.
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 12
  givenname: Daniela
  surname: Montaldi
  fullname: Montaldi, Daniela
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 13
  givenname: Nicholas
  surname: Webb
  fullname: Webb, Nicholas
  organization: Department of Paediatric Nephrology, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Academic Health Sciences Centre
– sequence: 14
  givenname: John
  surname: Keane
  fullname: Keane, John
  organization: Computer Science, University of Manchester
– sequence: 15
  givenname: Francisco X.
  surname: Castellanos
  fullname: Castellanos, Francisco X.
  organization: Hassenfeld Children’s Hospital at NYU Langone, Nathan S. Kline Institute for Psychiatric Research
– sequence: 16
  givenname: Alcino J.
  surname: Silva
  fullname: Silva, Alcino J.
  organization: Departments of Neurobiology, Psychiatry and Biobehavioral Sciences and Psychology, Integrative Center for Learning and Memory, Brain Research Institute, Brain Research Institute, University of California
– sequence: 17
  givenname: Sue
  surname: Huson
  fullname: Huson, Sue
  organization: Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Academic Health Sciences Centre
– sequence: 18
  givenname: Stephen
  surname: Williams
  fullname: Williams, Stephen
  organization: Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre
– sequence: 19
  givenname: D.
  surname: Gareth Evans
  fullname: Gareth Evans, D.
  organization: Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Academic Health Sciences Centre
– sequence: 20
  givenname: Richard
  surname: Emsley
  fullname: Emsley, Richard
  organization: Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester
– sequence: 21
  givenname: Jonathan
  orcidid: 0000-0002-0143-181X
  surname: Green
  fullname: Green, Jonathan
  email: jonathan.green@manchester.ac.uk
  organization: Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29484149$$D View this record in MEDLINE/PubMed
BookMark eNqNUl1r2zAUNaNj7br-gL0Mw2B0D-kkWf56KYSyj0LZYMu7uJavEwVZyiS5If31k-esJGOUyQhfrs85-N5zXiYnxhpMkteUXFFaFR88zRirZ4RW8dZk9vAsOWOEkxnLanZyUJ8mF96vSTwZ5ZyzF8kpq3nFKa_Pku13MK3tlcc2ldYEZ7WOZXAKdGq71Kv-HnyAoExsIoQeTUg761IYgvJ9Gvs7O5hlKldKtw5NulVhlRocnO1U42wPwXrl07DbYErTyx_zr4v5-1fJ8w60x4v9-zxZfPq4uPkyu_v2-fZmfjeTBSnCrIWaUd7Ismvasst5VlY0LzKsm6bDimWy5qxiUJQ5IOVxIUhbLChDSRknbXae3E6yrYW12DjVg9sJC0r8bli3FOCCkhpFC12bY1nmEgpeU1kXednQAspMciQdRC02aQ1mA7staP0oSIkYPRGTJyJ6IkZPxEMkXU-kzdD02Mq4PQf66E-Ovxi1Ekt7L_KK8TzjUeByL-DszwF9ENEsiVqDQTt4wQipqtFMFqFvJ-gS4jzKdDYqyhEu5jmrCsJKTiPq6h-o-LTYqxgB7FTsHxHeHRBWCDqsvNXRfmv8MfDN4ayPQ_5JWwSUE0A6673DTkg1RmvMHSj95BrpX8z_Wf3eLx-xZolOrO3gTEzbE6RfdccJxA
CitedBy_id crossref_primary_10_1038_s41398_018_0335_z
crossref_primary_10_1186_s13229_022_00488_4
crossref_primary_10_1186_s11689_025_09599_4
crossref_primary_10_3389_fpsyt_2020_585700
crossref_primary_10_1242_dmm_049422
crossref_primary_10_3389_fnmol_2019_00289
crossref_primary_10_1186_s40792_024_02062_x
crossref_primary_10_3390_children11010117
crossref_primary_10_1186_s13229_020_00372_z
crossref_primary_10_1016_j_jpsychires_2021_06_002
crossref_primary_10_1038_s41598_022_17873_x
crossref_primary_10_1016_j_clinph_2025_02_270
crossref_primary_10_1186_s12944_024_02075_3
crossref_primary_10_7759_cureus_36870
crossref_primary_10_1111_dmcn_16094
crossref_primary_10_1186_s13229_021_00458_2
crossref_primary_10_1016_j_pnpbp_2024_111176
crossref_primary_10_3390_ijms221810178
crossref_primary_10_1523_ENEURO_0392_19_2020
crossref_primary_10_3389_fpsyg_2022_795951
crossref_primary_10_1523_ENEURO_0461_22_2023
crossref_primary_10_1038_s41431_021_00892_z
crossref_primary_10_1080_14728222_2018_1465931
crossref_primary_10_1016_j_bpsc_2022_08_012
crossref_primary_10_1002_aur_2487
crossref_primary_10_1002_acn3_50952
crossref_primary_10_3389_fnins_2022_1045585
crossref_primary_10_3390_life11121365
crossref_primary_10_1016_j_isci_2023_108676
crossref_primary_10_1016_j_ibmed_2022_100073
crossref_primary_10_1007_s10803_021_05028_2
crossref_primary_10_3390_cells13080721
crossref_primary_10_1186_s13041_019_0517_5
crossref_primary_10_3390_applbiosci3010002
crossref_primary_10_1007_s00247_022_05322_w
crossref_primary_10_1016_j_jaac_2024_09_011
crossref_primary_10_1093_cercor_bhaa299
crossref_primary_10_1111_jcpp_12892
crossref_primary_10_12688_f1000research_25306_2
crossref_primary_10_12688_f1000research_25306_1
crossref_primary_10_1089_cap_2018_0159
crossref_primary_10_1523_ENEURO_0162_20_2020
crossref_primary_10_3390_children10091556
crossref_primary_10_1016_j_bpsgos_2021_08_005
crossref_primary_10_3390_genes12111746
crossref_primary_10_1016_j_cellsig_2020_109746
crossref_primary_10_1016_j_ejmg_2021_104281
crossref_primary_10_1016_j_euroneuro_2021_02_020
crossref_primary_10_1016_j_pharmthera_2021_107939
crossref_primary_10_1038_s41598_022_21907_9
crossref_primary_10_3389_fped_2023_1274972
crossref_primary_10_1002_aur_2427
Cites_doi 10.1016/j.ebiom.2016.04.005
10.1136/jnnp.57.12.1479
10.3233/JAD-2010-101179
10.1542/peds.2013-1868
10.1523/JNEUROSCI.0299-16.2016
10.1016/j.cub.2005.09.043
10.1177/0883073817702981
10.1017/S0954579405050297
10.1002/acn3.288
10.1097/MNM.0b013e3282f1bbf5
10.1002/ajmg.a.33139
10.1016/j.neulet.2012.03.009
10.1111/dmcn.12043
10.1016/j.jalz.2012.05.1890
10.1093/brain/aws368
10.1016/j.pediatrneurol.2011.06.016
10.1177/088307389701200807
10.1016/j.rasd.2013.10.003
10.1093/cercor/bhn031
10.1001/archneur.1988.00520290115023
10.1002/ajmg.a.31465
10.1002/nbm.3622
10.1001/jamapsychiatry.2016.2600
10.1002/ajmg.b.32280
10.1016/j.celrep.2013.08.011
10.1212/WNL.0000000000003435
10.1111/j.1469-8749.2006.tb01268.x
10.3174/ajnr.A3649
10.1016/j.phrs.2014.06.007
10.1371/journal.pone.0047854
10.1212/WNL.0000000000003044
10.1089/brain.2014.0334
10.1097/DBP.0b013e31817dc447
10.1002/sim.6386
10.1002/hbm.22937
10.1023/A:1022602400621
10.15274/NRJ-2014-10055
10.1186/1471-2377-13-131
10.1038/sj.npp.1300873
10.1146/annurev.pharmtox.45.120403.095748
10.1002/mrm.20784
10.1056/NEJMoa013171
10.1056/NEJM199912093412404
10.1016/j.neuroimage.2012.12.004
10.1038/tp.2015.78
10.1186/s13229-017-0166-4
10.1016/j.cell.2008.09.060
10.1038/nn.3822
10.1097/00004583-200312000-00011
10.1017/S0012162201001876
10.1001/jama.300.3.287
10.1186/s40364-016-0076-1
10.1016/j.pnpbp.2015.11.013
10.1016/S1474-4422(13)70227-8
10.1007/s10545-007-0537-7
10.1016/j.neuroimage.2007.04.060
10.1016/j.brainresbull.2010.12.002
ContentType Journal Article
Contributor Ellicott, Ruth
Wagstaffe, Rose
Bethell, Helen
Patel, Sonia
Acharya, Jamuna
Bradbury, Alyson
Prem, Catherine
Mercatali, Giangiacomo
Lewis, Lauren
Sharif, Saghira Malik
Lam, Wayne
Quarrell, Oliver
Bassi, Zahabiyah
Hupton, Eileen
Dobbie, Angus
Harrower, Neil
Velandy, Srilaxmi
Drimer, Ruth
Harrison, Emma
West, Siobhan
Tricker, Karen
Kapasi, Akhtar
Howard, Elizabeth
Vassallo, Grace
Eelloo, Judith
Splitt, Miranda
Moon, Rachel
Musson, Susan
Jones, Rachel
Steiger, Christine
Campbell, Suzanne
Tobin, Hannah
Horridge, Karen
Burkitt-Wright, Emma
Contributor_xml – sequence: 1
  givenname: Suzanne
  surname: Campbell
  fullname: Campbell, Suzanne
– sequence: 2
  givenname: Ruth
  surname: Ellicott
  fullname: Ellicott, Ruth
– sequence: 3
  givenname: Emma
  surname: Harrison
  fullname: Harrison, Emma
– sequence: 4
  givenname: Akhtar
  surname: Kapasi
  fullname: Kapasi, Akhtar
– sequence: 5
  givenname: Giangiacomo
  surname: Mercatali
  fullname: Mercatali, Giangiacomo
– sequence: 6
  givenname: Rachel
  surname: Moon
  fullname: Moon, Rachel
– sequence: 7
  givenname: Hannah
  surname: Tobin
  fullname: Tobin, Hannah
– sequence: 8
  givenname: Srilaxmi
  surname: Velandy
  fullname: Velandy, Srilaxmi
– sequence: 9
  givenname: Rose
  surname: Wagstaffe
  fullname: Wagstaffe, Rose
– sequence: 10
  givenname: Emma
  surname: Burkitt-Wright
  fullname: Burkitt-Wright, Emma
– sequence: 11
  givenname: Grace
  surname: Vassallo
  fullname: Vassallo, Grace
– sequence: 12
  givenname: Siobhan
  surname: West
  fullname: West, Siobhan
– sequence: 13
  givenname: Judith
  surname: Eelloo
  fullname: Eelloo, Judith
– sequence: 14
  givenname: Eileen
  surname: Hupton
  fullname: Hupton, Eileen
– sequence: 15
  givenname: Sonia
  surname: Patel
  fullname: Patel, Sonia
– sequence: 16
  givenname: Elizabeth
  surname: Howard
  fullname: Howard, Elizabeth
– sequence: 17
  givenname: Karen
  surname: Tricker
  fullname: Tricker, Karen
– sequence: 18
  givenname: Lauren
  surname: Lewis
  fullname: Lewis, Lauren
– sequence: 19
  givenname: Angus
  surname: Dobbie
  fullname: Dobbie, Angus
– sequence: 20
  givenname: Ruth
  surname: Drimer
  fullname: Drimer, Ruth
– sequence: 21
  givenname: Saghira Malik
  surname: Sharif
  fullname: Sharif, Saghira Malik
– sequence: 22
  givenname: Zahabiyah
  surname: Bassi
  fullname: Bassi, Zahabiyah
– sequence: 23
  givenname: Jamuna
  surname: Acharya
  fullname: Acharya, Jamuna
– sequence: 24
  givenname: Wayne
  surname: Lam
  fullname: Lam, Wayne
– sequence: 25
  givenname: Neil
  surname: Harrower
  fullname: Harrower, Neil
– sequence: 26
  givenname: Oliver
  surname: Quarrell
  fullname: Quarrell, Oliver
– sequence: 27
  givenname: Alyson
  surname: Bradbury
  fullname: Bradbury, Alyson
– sequence: 28
  givenname: Miranda
  surname: Splitt
  fullname: Splitt, Miranda
– sequence: 29
  givenname: Susan
  surname: Musson
  fullname: Musson, Susan
– sequence: 30
  givenname: Rachel
  surname: Jones
  fullname: Jones, Rachel
– sequence: 31
  givenname: Helen
  surname: Bethell
  fullname: Bethell, Helen
– sequence: 32
  givenname: Catherine
  surname: Prem
  fullname: Prem, Catherine
– sequence: 33
  givenname: Karen
  surname: Horridge
  fullname: Horridge, Karen
– sequence: 34
  givenname: Christine
  surname: Steiger
  fullname: Steiger, Christine
Copyright The Author(s). 2018
COPYRIGHT 2018 BioMed Central Ltd.
Copyright_xml – notice: The Author(s). 2018
– notice: COPYRIGHT 2018 BioMed Central Ltd.
CorporateAuthor SANTA Consortium
CorporateAuthor_xml – name: SANTA Consortium
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/s13229-018-0190-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList



MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerLink Open Access Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2040-2392
EndPage 13
ExternalDocumentID oai_doaj_org_article_dafd5e775ca6491c9657b16a73c4e0fa
oai:kclpure.kcl.ac.uk:publications/3080316f-a78b-4966-9c10-4b9733c55a79
PMC5824534
A528602741
29484149
10_1186_s13229_018_0190_z
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United Kingdom
GeographicLocations_xml – name: United Kingdom
GrantInformation_xml – fundername: Central Manchester University Hospitals NHS Foundation Trust
  grantid: R02145
  funderid: http://dx.doi.org/10.13039/100008183
– fundername: NIBIB NIH HHS
  grantid: P41 EB015909
– fundername: Medical Research Council
  grantid: G0600485
– fundername: Medical Research Council
  grantid: MR/K005863/1
– fundername: Medical Research Council
  grantid: G0501110
– fundername: Medical Research Council
  grantid: G1100781
– fundername: Medical Research Council
  grantid: G0401546
– fundername: NIBIB NIH HHS
  grantid: R01 EB016089
– fundername: Medical Research Council
  grantid: MR/R006164/1
– fundername: Department of Health
  grantid: NIHR/CS/010/021
– fundername: ;
  grantid: R02145
GroupedDBID ---
0R~
53G
5VS
7RV
7X7
88E
8AO
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFS
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BKEYQ
BKNYI
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
K9-
KQ8
M0R
M1P
M2M
M48
M~E
NAPCQ
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PSYQQ
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
AAYXX
CITATION
2VQ
4.4
AHSBF
ALIPV
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c606t-da9214bc7fbd7f543781563e9bbfe823c94282a675ae14322e1de612ec1240d3
IEDL.DBID M48
ISSN 2040-2392
IngestDate Tue Oct 14 18:58:28 EDT 2025
Sun Oct 26 04:11:49 EDT 2025
Tue Sep 30 16:56:19 EDT 2025
Fri Sep 05 06:57:03 EDT 2025
Mon Oct 20 22:04:42 EDT 2025
Mon Oct 20 16:45:29 EDT 2025
Thu May 22 21:16:04 EDT 2025
Mon Jul 21 06:05:40 EDT 2025
Wed Oct 01 02:32:47 EDT 2025
Thu Apr 24 23:01:38 EDT 2025
Sat Sep 06 07:30:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Neuroimaging
Autism
Neurofibromatosis type 1
Statin
Simvastatin
Randomised controlled trial
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-da9214bc7fbd7f543781563e9bbfe823c94282a675ae14322e1de612ec1240d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-0143-181X
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13229-018-0190-z
PMID 29484149
PQID 2008884142
PQPubID 23479
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_dafd5e775ca6491c9657b16a73c4e0fa
unpaywall_primary_10_1186_s13229_018_0190_z
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5824534
proquest_miscellaneous_2008884142
gale_infotracmisc_A528602741
gale_infotracacademiconefile_A528602741
gale_healthsolutions_A528602741
pubmed_primary_29484149
crossref_citationtrail_10_1186_s13229_018_0190_z
crossref_primary_10_1186_s13229_018_0190_z
springer_journals_10_1186_s13229_018_0190_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-02-22
PublicationDateYYYYMMDD 2018-02-22
PublicationDate_xml – month: 02
  year: 2018
  text: 2018-02-22
  day: 22
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle Brain, Cognition and Behavior
PublicationTitle Molecular autism
PublicationTitleAbbrev Molecular Autism
PublicationTitleAlternate Mol Autism
PublicationYear 2018
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References W Li (190_CR18) 2005; 15
SN Tomson (190_CR16) 2015; 36
P Balestri (190_CR53) 1994; 57
L Krab (190_CR23) 2008; 300
P Mengotti (190_CR51) 2011; 84
S Hyman (190_CR2) 2007; 4812
F Mainberger (190_CR22) 2013; 13
T van der Vaart (190_CR24) 2013; 12
JE Lainhart (190_CR27) 2006; 140
D Evans (190_CR1) 2010; 152A
DA Mayes (190_CR10) 2013; 4
CE Bearden (190_CR20) 2016; 3
D Ben Bashat (190_CR50) 2007; 37
IR Violante (190_CR12) 2016; 87
DG Evans (190_CR43) 2016; 7
S Garg (190_CR4) 2013; 132
K Conners (190_CR35) 1998; 26
L Beason-Held (190_CR55) 2012; 8
Y Cui (190_CR8) 2008; 135
M Aman (190_CR32) 1994
K Vermeulen (190_CR39) 2015; 34
JT McCracken (190_CR36) 2002; 347
AM Kaplan (190_CR52) 1997; 12
ET Petersen (190_CR40) 2006; 55
MH Johnson (190_CR56) 2005; 17
M Mikkelsen (190_CR45) 2016; 29
JK Liao (190_CR57) 2005; 45
KA Doyle-Thomas (190_CR48) 2014; 8
V Mautner (190_CR3) 2002; 44
S Leucht (190_CR34) 2006; 31
AM Malfitano (190_CR59) 2014; 88
KW Yeom (190_CR14) 2013; 34
KH Karlsgodt (190_CR15) 2012; 7
C Chabernaud (190_CR21) 2012; 515
Q Ling (190_CR58) 2016; 66
LE Arnold (190_CR33) 2003; 42
M Kayano (190_CR28) 2016; 4
190_CR5
SJ Kiddle (190_CR29) 2015; 5
R Buchert (190_CR54) 2008; 29
E Berry-Kravis (190_CR31) 2008; 29
JM Payne (190_CR25) 2016; 87
F Pedregosa (190_CR41) 2011; 12
M Loitfelder (190_CR17) 2015; 5
IR Violante (190_CR13) 2013; 136
D Haas (190_CR37) 2007; 30
M Acosta (190_CR19) 2011; 45
SM Morris (190_CR6) 2016; 73
National Institutes of Health Consensus Development Conference (190_CR26) 1988; 45
AI Molosh (190_CR7) 2014; 17
PG Mullins (190_CR38) 2014; 86
SK Sundaram (190_CR49) 2008; 18
H Ito (190_CR47) 2017; 32
S Garg (190_CR42) 2013; 55
S Sierra (190_CR44) 2011; 23
J Goncalves (190_CR46) 2017; 8
G Ertan (190_CR11) 2014; 27
A Ishii (190_CR9) 2016; 36
A Sandler (190_CR30) 1999; 341
References_xml – volume: 7
  start-page: 212
  year: 2016
  ident: 190_CR43
  publication-title: EBioMed
  doi: 10.1016/j.ebiom.2016.04.005
– volume: 57
  start-page: 1479
  issue: 12
  year: 1994
  ident: 190_CR53
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.57.12.1479
– volume: 23
  start-page: 307
  issue: 2
  year: 2011
  ident: 190_CR44
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-2010-101179
– volume: 132
  start-page: e1642
  issue: 6
  year: 2013
  ident: 190_CR4
  publication-title: Pediatrics
  doi: 10.1542/peds.2013-1868
– volume: 36
  start-page: 6471
  issue: 24
  year: 2016
  ident: 190_CR9
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.0299-16.2016
– volume: 15
  start-page: 1961
  issue: 21
  year: 2005
  ident: 190_CR18
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2005.09.043
– volume: 32
  start-page: 731
  issue: 8
  year: 2017
  ident: 190_CR47
  publication-title: J Child Neurol
  doi: 10.1177/0883073817702981
– volume: 17
  start-page: 599
  issue: 3
  year: 2005
  ident: 190_CR56
  publication-title: Dev Psychopathol
  doi: 10.1017/S0954579405050297
– volume: 3
  start-page: 266
  issue: 4
  year: 2016
  ident: 190_CR20
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.288
– volume: 29
  start-page: 17
  issue: 1
  year: 2008
  ident: 190_CR54
  publication-title: Nucl Med Commun
  doi: 10.1097/MNM.0b013e3282f1bbf5
– volume: 152A
  start-page: 327
  year: 2010
  ident: 190_CR1
  publication-title: Am J Med Genet
  doi: 10.1002/ajmg.a.33139
– volume: 515
  start-page: 28
  year: 2012
  ident: 190_CR21
  publication-title: Neurosci Lett
  doi: 10.1016/j.neulet.2012.03.009
– volume: 55
  start-page: 139
  issue: 2
  year: 2013
  ident: 190_CR42
  publication-title: Dev Med Child Neurol
  doi: 10.1111/dmcn.12043
– volume: 8
  start-page: 701
  issue: 4
  year: 2012
  ident: 190_CR55
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2012.05.1890
– volume: 136
  start-page: 918
  issue: Pt 3
  year: 2013
  ident: 190_CR13
  publication-title: Brain
  doi: 10.1093/brain/aws368
– volume: 45
  start-page: 241
  year: 2011
  ident: 190_CR19
  publication-title: Pediatr Neurol
  doi: 10.1016/j.pediatrneurol.2011.06.016
– volume: 12
  start-page: 499
  issue: 8
  year: 1997
  ident: 190_CR52
  publication-title: J Child Neurol
  doi: 10.1177/088307389701200807
– volume: 8
  start-page: 44
  issue: 1
  year: 2014
  ident: 190_CR48
  publication-title: Res Autism Spectr Disord
  doi: 10.1016/j.rasd.2013.10.003
– volume: 18
  start-page: 2659
  issue: 11
  year: 2008
  ident: 190_CR49
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/bhn031
– volume: 45
  start-page: 575
  year: 1988
  ident: 190_CR26
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1988.00520290115023
– volume: 140
  start-page: 2257
  issue: 21
  year: 2006
  ident: 190_CR27
  publication-title: Am J Med Genet A
  doi: 10.1002/ajmg.a.31465
– volume: 29
  start-page: 1644
  issue: 11
  year: 2016
  ident: 190_CR45
  publication-title: NMR Biomed
  doi: 10.1002/nbm.3622
– volume: 73
  start-page: 1276
  issue: 12
  year: 2016
  ident: 190_CR6
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2016.2600
– ident: 190_CR5
  doi: 10.1002/ajmg.b.32280
– volume: 4
  start-page: 1197
  issue: 6
  year: 2013
  ident: 190_CR10
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2013.08.011
– volume: 87
  start-page: 2575
  issue: 24
  year: 2016
  ident: 190_CR25
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000003435
– volume: 4812
  start-page: 973
  year: 2007
  ident: 190_CR2
  publication-title: Dev Med Child Neurol
  doi: 10.1111/j.1469-8749.2006.tb01268.x
– volume: 34
  start-page: 1823
  issue: 9
  year: 2013
  ident: 190_CR14
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A3649
– volume: 88
  start-page: 74
  year: 2014
  ident: 190_CR59
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2014.06.007
– volume: 7
  start-page: e47854
  issue: 10
  year: 2012
  ident: 190_CR15
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0047854
– volume: 87
  start-page: 897
  issue: 9
  year: 2016
  ident: 190_CR12
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000003044
– volume: 12
  start-page: 2825
  year: 2011
  ident: 190_CR41
  publication-title: J Mach Learn Res
– volume: 5
  start-page: 312
  issue: 5
  year: 2015
  ident: 190_CR17
  publication-title: Brain Connectivity
  doi: 10.1089/brain.2014.0334
– volume: 29
  start-page: 293
  year: 2008
  ident: 190_CR31
  publication-title: J Dev Behav Pediatr
  doi: 10.1097/DBP.0b013e31817dc447
– volume: 34
  start-page: 1012
  issue: 6
  year: 2015
  ident: 190_CR39
  publication-title: Stat Med
  doi: 10.1002/sim.6386
– volume: 36
  start-page: 4566
  issue: 11
  year: 2015
  ident: 190_CR16
  publication-title: Hum Brain Mapp
  doi: 10.1002/hbm.22937
– volume: 26
  start-page: 257
  issue: 4
  year: 1998
  ident: 190_CR35
  publication-title: J Abnorm Child Psychol
  doi: 10.1023/A:1022602400621
– volume: 27
  start-page: 616
  issue: 5
  year: 2014
  ident: 190_CR11
  publication-title: Neuroradiol J
  doi: 10.15274/NRJ-2014-10055
– volume: 13
  start-page: 131
  year: 2013
  ident: 190_CR22
  publication-title: BMC Neurol
  doi: 10.1186/1471-2377-13-131
– volume: 31
  start-page: 406
  issue: 2
  year: 2006
  ident: 190_CR34
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300873
– volume: 45
  start-page: 89
  year: 2005
  ident: 190_CR57
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.45.120403.095748
– volume: 55
  start-page: 219
  issue: 2
  year: 2006
  ident: 190_CR40
  publication-title: Magn Reson Med
  doi: 10.1002/mrm.20784
– volume: 347
  start-page: 314
  issue: 5
  year: 2002
  ident: 190_CR36
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa013171
– volume: 341
  start-page: 1801
  issue: 24
  year: 1999
  ident: 190_CR30
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199912093412404
– volume: 86
  start-page: 43
  year: 2014
  ident: 190_CR38
  publication-title: NeuroImage
  doi: 10.1016/j.neuroimage.2012.12.004
– volume-title: Aberrant behaviour checklist––community
  year: 1994
  ident: 190_CR32
– volume: 5
  start-page: e584
  year: 2015
  ident: 190_CR29
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2015.78
– volume: 8
  start-page: 47
  year: 2017
  ident: 190_CR46
  publication-title: Mol Autism
  doi: 10.1186/s13229-017-0166-4
– volume: 135
  start-page: 549
  issue: 3
  year: 2008
  ident: 190_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2008.09.060
– volume: 17
  start-page: 1583
  issue: 11
  year: 2014
  ident: 190_CR7
  publication-title: Nat Neurosci
  doi: 10.1038/nn.3822
– volume: 42
  start-page: 1443
  issue: 12
  year: 2003
  ident: 190_CR33
  publication-title: J Am Acad Child Adolesc Psychiatry
  doi: 10.1097/00004583-200312000-00011
– volume: 44
  start-page: 164
  issue: 3
  year: 2002
  ident: 190_CR3
  publication-title: Dev Med Child Neurol
  doi: 10.1017/S0012162201001876
– volume: 300
  start-page: 287
  issue: 3
  year: 2008
  ident: 190_CR23
  publication-title: JAMA
  doi: 10.1001/jama.300.3.287
– volume: 4
  start-page: 22
  year: 2016
  ident: 190_CR28
  publication-title: Biomarker Res
  doi: 10.1186/s40364-016-0076-1
– volume: 66
  start-page: 80
  year: 2016
  ident: 190_CR58
  publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2015.11.013
– volume: 12
  start-page: 1076
  issue: 11
  year: 2013
  ident: 190_CR24
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(13)70227-8
– volume: 30
  start-page: 375
  issue: 3
  year: 2007
  ident: 190_CR37
  publication-title: J Inherit Metab Dis
  doi: 10.1007/s10545-007-0537-7
– volume: 37
  start-page: 40
  issue: 1
  year: 2007
  ident: 190_CR50
  publication-title: NeuroImage
  doi: 10.1016/j.neuroimage.2007.04.060
– volume: 84
  start-page: 189
  issue: 2
  year: 2011
  ident: 190_CR51
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2010.12.002
SSID ssj0000314442
Score 2.3934693
Snippet Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models,...
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but...
Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models,...
Abstract Background Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 12
SubjectTerms Autism
Autistic Disorder - blood
Autistic Disorder - complications
Autistic Disorder - drug therapy
Biomarkers - blood
Brain - diagnostic imaging
Child
Complications and side effects
Dosage and administration
Drug therapy
Emerging rare genetic and genomic syndromes in autism and developmental delay
Female
gamma-Aminobutyric Acid - blood
Glutamic Acid - blood
Human Genetics
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
Medicine
Medicine & Public Health
Mitogen-Activated Protein Kinases - blood
Neurofibromatosis
Neurofibromatosis 1 - blood
Neurofibromatosis 1 - complications
Neurofibromatosis 1 - drug therapy
Neurofibromatosis type 1
Neuroimaging
Neurology
Neuropsychology
Neurosciences
Patient outcomes
Pediatrics
Psychiatry
Psychological aspects
Randomised controlled trial
Simvastatin
Simvastatin - administration & dosage
Simvastatin - adverse effects
Simvastatin - therapeutic use
Statin
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYll7aHktKXm7RVodBHMLEl2bKO25IQCs2h3UJuQi_ThY0d6t2G5Nd3RvaadQvJJTdjjcHSfBp9Y8-DkHcyd1YJz1OrrEyFt2VqjA2p594Iw4OzBrORv52WJz_F17PibKvVF8aE9eWB-4U79Kb2RZCycKYUKneqLKTNSyO5EyGrIzXKKrXlTEUbzMFREGz4jZlX5WGHbheGBmHslsrS68lBFOv1_2-Vt46lf0Mmx_-mD8n9dXNhri7Ncrl1NB3vkkcDp6Szfi6Pyb3QPCGX303jW9Bi8HSIR1_CZezSQduadovzPwbTiRYNHaPNKVBYagCL3TmF-1doCugm35viN1saC2DW4GS3wHXbbtFR_IpLc_rhx-x0Pvv4lMyPj-ZfTtKhy0LqwHlZpd4olgvrZG29rAvBJRaQ4UFZW4eKcafAQ2EGHAsTgFwxFnIfgBcFB9Qg8_wZ2WnaJrwgVCrry8oD5URe4nJlmFQZN4V3Iq-8SUi2WXHthgrk2AhjqaMnUpW6V5IGJWlUkr5OyKfxkYu-_MZNwp9RjaMgVs6ONwBPesCTvg1PCXmDINB9Guq4__WsYNiuCwhYQt5HCbQA8PrODIkMsAhYS2siuT-RBJ27yfDbDdA0DmG4WxPadRd7g1aVyAVLyPMeeOOsmBI4ohIiJ5CcTHs60ix-xcLhRcVEwUVCDjbg1YPF6m5a1YMR37fr4OVd6GCPPGBxo7KUsX2ys_q9Dq-A-63s67jN_wLIxFbu
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF-0gtYH8dto1RUEtSWYbDbZ7ONZLEVoH_SEvi37FTy4JqW5s7R_vTN7e-GiUvEtZCch2ZnZ_c3OFyFvRW6N5K5IjTQi5c5UqdbGp65wmuvCW6MxG_nouDr8zr-clCexWDTmwmz67_O6-tijtYQRPRhyJbP06ia5BXtUFfyy1f5wnIJV2Dln0W_51ydHO08o0P_nMryxD_0eIzk4Su-SO8v2TF9e6Pl8Yy86uE_uRRBJJyuuPyA3fPuQ3D6KbvJH5OKrbl0HHPSOxlj0OVyGDh20a2g_O_2pMZVo1tIh0pwCfKUa5LA_pXD_EpcBus71pnheS0PxywYM7A5wbtfPeoonuDSn779NjqeTD4_J9ODzdP8wjR0WUguGyyJ1WrKcGysa40RT8kJg8ZjCS2MaX7PCSrBOmAajQnsAVoz53HnARN4CLMhc8YRstV3rnxEqpHFV7QBuIiaxudRMyKzQpbM8r51OSLaefGVj9XFsgjFXwQqpK7XilwJ-KeSXukrI7vDI2ar0xnXEn5CjAyFWzQ43QJhUVELldONKL0RpdcVlbmVVCpNXWhSW-6yBj3yN8qBWKaiD7qtJybBVF4CvhLwLFKj98PlWxyQGmASsozWi3BlRAs_taPjNWuYUDmGoW-u7ZR_6gtY1zzlLyNOVDA5_xSTHEZkQMZLO0W-PR9rZj1A0vKwZLwuekL21HKu4WvXXzereIOr_5sHz_3r3C7LNgnKylLEdsrU4X_qXAPAW5lVQ7V_8mUmy
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1Lb9NAEF6V9gAceIhXoMAiIfGonMbr9WOPaaEUBC1q06o9rfZliJraUZxQtRf-Cj-VGcd26yIVceIUyzvR2rMzs99450HIy9g3WnAbeFro2ONWR55S2nk2sIqrwBmtMBv5y1a0ucc_HYQHC-RnnQtzZEbj2cR14bdKpjrB49uRK1bBV0sQva_ugI-dAxeclVU89wguyy4XMk_l7uDjfn9ne1fWgeWWwZLrCbD8FLa7RH7Y_vxO7uc7cn1drh3K7tim18hSFAKYXyRLe1tf-4fYkg5j7RjAh-os1E-i1QJ9N4wvwgAw0fPOWrtZWfT_T9N-YW-7HHfZHL7eJNdn2VidnqjR6ML-tnGb_Ko5Mw9rOerOprprzi4VjfyPrLtDblXYmfbnwn6XLLjsHjk5n4yeT0bLyWie0mJ4_ENh2tQwo01UPQWoThXoXHFM4f4pmjxa57VT_DZNy0Kf6VBPcsD0eTEsKH6tpj59vdvfGvTf3CeDjfeD9U2v6ibhGXDSpp5VgvlcmzjVNk5DHsRYKCdwQuvUJSwwAjwxpsCBUg5AJGPOtw7wnzMAgXo2eEAWszxzjwiNhbZRYgFaI_4yvlAsFr1AhdZwP7GqQ3q1UEhTVVrHhh8jWXpcSSTnciSRoyhH8qxD3jZ_Gc_LjFxFvIaS1hBihfDyRj75JiuDI61KbejiODQq4sI3Igpj7UcqDgx3vRQe8jnKqZyn2zZ2TvZDhm3JAGh2yKuSAi0dPL5RVcIGMAGlqkW53KKENTet4Re1LkgcwrC-zOWzouyBmiTc56xDHs51o3krJjiOiA6JW1rTeu32SDb8XhZIDxPGw4B3yEqtX7KyzMVVXF1pVPDva_D4n6ifkBusNBrMY2yZLE4nM_cUwOxUP6sMzm8IEqJq
  priority: 102
  providerName: Unpaywall
Title Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)
URI https://link.springer.com/article/10.1186/s13229-018-0190-z
https://www.ncbi.nlm.nih.gov/pubmed/29484149
https://www.proquest.com/docview/2008884142
https://pubmed.ncbi.nlm.nih.gov/PMC5824534
https://kclpure.kcl.ac.uk/ws/files/88881148/Randomised_controlled_trial_of_STIVAROS_Published22February2018_GOLD_VoR_CC_BY_.pdf
https://doaj.org/article/dafd5e775ca6491c9657b16a73c4e0fa
UnpaywallVersion submittedVersion
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central_OA刊
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: RBZ
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate [EBSCO]
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: ABDBF
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: GX1
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: BENPR
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central Health & Medical Collection (via ProQuest)
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: 7X7
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: 8C1
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal - Open Access
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: M48
  dateStart: 20100601
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: AAJSJ
  dateStart: 20101201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Open Access Journals
  customDbUrl:
  eissn: 2040-2392
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000314442
  issn: 2040-2392
  databaseCode: C6C
  dateStart: 20100112
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELf28QA8IBBfgVGMhITEFNY4Thw_INRVm6ZKq6axSuPJ8legUpeMpgW6v56zm0QLTOWlqXxOFPvu7N8594HQOxZpxamJQ8UVC6lRaSilsqGJjaQytlpJF418Ok5PJnR0mVxuoaa8VT2B1Z2mnasnNZnPPv7-sfoMCv_JK3yWHlTOonJeP84ti_fDm220CxsVd5UcTmu07xfmGKwHX06HOD86AtCg_s5551M6O5VP6P_vsn1r3_rbp7L9sPoA3VsW13L1S85mt_au40foYQ068WAtJY_Rli2eoPJcFqYENluDa4f1Gfz1ZTxwmeNqevVTunijaYFbd3QMGBdLENbqCkP7yq0VuAkIx-5QF_sMmTlY4SWA4bKaVtgd8-LoKbo4ProYnoR1-YVQg1WzCI3kJKJKs1wZlic0Zi6zTGy5UrnNSKw5mC5EgsUhLaAuQmxkLAAmqwEz9E38DO0UZWFfIMy4MmlmAIs6wKIjLgnj_VgmRtMoMzJA_Wamha5Tk7sKGTPhTZQsFWvmCGCOcMwRNwH60N5yvc7LsanzoWNf29Gl1PYN5fybqDVUGJmbxDKWaJlSHmmeJkxFqWSxprafw0u-ccwX6_jUdmEQg4S4Ol6AzAL03vdwwgqvr2Ud4QCT4JJsdXrudXoCr3WH_LYRMOFIzg-usOWy8kVDs4xGlATo-Vrg2lERTh2FB4h1RLEz7C6lmH73GcWTjNAkpgHab4RWNJq4aVb3W7n-Pw9ebh7yK3SfeNUjISF7aGcxX9rXAPcWqoe22SWD32wY9dDuYDD6MoLr4dH47Bxah-mw5w9Sel7ZgTIZnw2-_gG3Blit
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglSgcEG8ChRoJCWgVsXGcOD4GRLUs3T3QRerN8iuw0japmi5V--vxeJ2oAVTELYonUeJ5-Bt7Hgi9ZolWnJo0VlyxmBqVx1IqG5vUSCpTq5WEbOTpLB9_o5Oj7CjkcbddtHt3JOkttVfrIn_fgt8EsT0QfMVH8eVNtAkxVk4bN8tycjjpt1agIjulJJxh_vXZwSrki_X_aZKvrEm_x0v2h6Z30NaqPpEX53K5vLIu7d9DdwOgxOVaAu6jG7Z-gG5Nw5H5Q3T-Vdamcdy0Boe49KW79N06cFPhdnH8U0Ja0aLGfdQ5dlAWSyeT7TF29y_AJOAu7xvD3i32hTAr52w3DvM27aLFsJuLE_z2sJzNy3eP0Hz_0_zjOA7dFmLtnJiz2EhOEqo0q5RhVUZTBoVkUsuVqmxBUs2dp0KkczCkdSCLEJsY6_CR1Q4ijEz6GG3UTW2fIsy4MnlhHPQEfKITLgnjo1RmRtOkMDJCo27yhQ6VyKEhxlJ4j6TIxZpfwvFLAL_EZYR2-0dO1mU4riP-ABztCaGCtr_RnH4XQSGFkZXJLGOZljnlieZ5xlSSS5ZqakeV-8gdkAexTkft7YAoMwJtuxwQi9AbTwGWwH2-liGhwU0C1NQaUG4PKB3P9WD4VSdzAoYg7K22zar1PUKLgiaUROjJWgb7vyKcwgiPEBtI5-C3hyP14ocvIJ4VhGYpjdBeJ8ciWK72ulnd60X93zx49l_v3kFb4_n0QBx8nn15jm4Tr6gkJmQbbZydruwLB_zO1Mug6L8AfpdSCw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELagSAUeEDeBQo2EBLSKunGcOH5cFqpydIVgkfpm-QqstE1WzS5V--uZyaUGUBFvUTyJEs_Y_sae-YaQFyKyRnIXh0YaEXJn0lBr40MXO8117K3RmI18OE0PvvEPR8lRW-e06qLduyPJJqcBWZqK1d7S5c0Qz9K9Cn0ojPPBQCw5Cs-vkmscFjcsYTBJJ_0mC3Kzc87a08y_PjlYj2ra_j8n5wur0--Rk_3x6U1yfV0s9dmpXiwurFD7t8mtFlrScWMLd8gVX9wlm4ft4fk9cvpFF64EvXpH2wj1BVzWdTtomdNqfvxTY4LRvKB9_DkFUEs1WGd1TOH-GU4OtMsAp7iLS2tKzBzc7hLQb1nNK4r7ujSir76Op7Px6_tktv9uNjkI27oLoQV3ZhU6LVnEjRW5cSJPeCyQUib20pjcZyy2EnwWpsHV0B7gFmM-ch6QkrcAFkYufkA2irLwjwgV0rg0cwBCEanYSGom5CjWibM8ypwOyKjrfGVbTnIsjbFQtW-SparRlwJ9KdSXOg_ITv_IsiHkuEz4DWq0F0Qu7fpGefJdtUNTOZ27xAuRWJ1yGVmZJsJEqRax5X6Uw0duoz2oJjG1nxHUOGFYwAsgWUBe1hI4J8DnW92mNkAnILvWQHJrIAk6t4Pm553NKWzCALjCl-uqrhaaZTziLCAPGxvs_4pJji0yIGJgnYPfHrYU8x81lXiSMZ7EPCC7nR2rdg6rLuvV3d7U_62Dx__17m2y-fntvvr0fvrxCbnB6nHKQsa2yMbqZO2fAgJcmWf1KP8FcmVU6A
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1Lb9NAEF6V9gAceIhXoMAiIfGonMbr9WOPaaEUBC1q06o9rfZliJraUZxQtRf-Cj-VGcd26yIVceIUyzvR2rMzs99450HIy9g3WnAbeFro2ONWR55S2nk2sIqrwBmtMBv5y1a0ucc_HYQHC-RnnQtzZEbj2cR14bdKpjrB49uRK1bBV0sQva_ugI-dAxeclVU89wguyy4XMk_l7uDjfn9ne1fWgeWWwZLrCbD8FLa7RH7Y_vxO7uc7cn1drh3K7tim18hSFAKYXyRLe1tf-4fYkg5j7RjAh-os1E-i1QJ9N4wvwgAw0fPOWrtZWfT_T9N-YW-7HHfZHL7eJNdn2VidnqjR6ML-tnGb_Ko5Mw9rOerOprprzi4VjfyPrLtDblXYmfbnwn6XLLjsHjk5n4yeT0bLyWie0mJ4_ENh2tQwo01UPQWoThXoXHFM4f4pmjxa57VT_DZNy0Kf6VBPcsD0eTEsKH6tpj59vdvfGvTf3CeDjfeD9U2v6ibhGXDSpp5VgvlcmzjVNk5DHsRYKCdwQuvUJSwwAjwxpsCBUg5AJGPOtw7wnzMAgXo2eEAWszxzjwiNhbZRYgFaI_4yvlAsFr1AhdZwP7GqQ3q1UEhTVVrHhh8jWXpcSSTnciSRoyhH8qxD3jZ_Gc_LjFxFvIaS1hBihfDyRj75JiuDI61KbejiODQq4sI3Igpj7UcqDgx3vRQe8jnKqZyn2zZ2TvZDhm3JAGh2yKuSAi0dPL5RVcIGMAGlqkW53KKENTet4Re1LkgcwrC-zOWzouyBmiTc56xDHs51o3krJjiOiA6JW1rTeu32SDb8XhZIDxPGw4B3yEqtX7KyzMVVXF1pVPDva_D4n6ifkBusNBrMY2yZLE4nM_cUwOxUP6sMzm8IEqJq
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomised+controlled+trial+of+simvastatin+treatment+for+autism+in+young+children+with+neurofibromatosis+type+1&rft.jtitle=Molecular+autism&rft.au=Stivaros%2C+Stavros&rft.au=Garg%2C+Shruti&rft.au=Tziraki%2C+Maria&rft.au=Cai%2C+Ying&rft.date=2018-02-22&rft.pub=BioMed+Central+Ltd&rft.issn=2040-2392&rft.eissn=2040-2392&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1186%2Fs13229-018-0190-z&rft.externalDocID=A528602741
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-2392&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-2392&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-2392&client=summon